



SAFETY DATA SHEET

Revision date 18-Mar-2022

Version 2

Page 1 / 14

Section 1: IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING

1.1. Product identifier

Product Name Linezolid Injection (Hospira, Inc.)
Product Code(s) PZ03154
Trade Name: Not applicable
Chemical Family: Mixture

1.2. Relevant identified uses of the substance or mixture and uses advised against

Recommended Use Pharmaceutical product used as antibiotic agent

1.3. Details of the supplier of the safety data sheet

Hospira, A Pfizer Company
275 North Field Drive
Lake Forest, Illinois 60045
1-800-879-3477

Pfizer Ireland Pharmaceuticals
OSG Building
Ringaskiddy, Co. Cork.
Ireland
+353 21 4378701

1.4. Emergency telephone number

Emergency Telephone Chemtrec 1-800-424-9300 International Chemtrec (24 hours):+1-703-527-3887
E-mail address pfizer-MSDS@pfizer.com

Section 2: HAZARDS IDENTIFICATION

2.1. Classification of the substance or mixture

GHS - Classification: Not classified as hazardous

2.2. Label elements

Signal word Not required

Hazard statements Non-hazardous in accordance with international standards for workplace safety.

2.3. Other hazards

Other hazards An Occupational Exposure Value has been established for one or more of the ingredients (see Section 8).

SAFETY DATA SHEET

Product Name Linezolid Injection (Hospira, Inc.)
Revision date 18-Mar-2022

Page 2 / 14
Version 2

Note: This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

Section 3: COMPOSITION/INFORMATION ON INGREDIENTS

3.1 Substances

Substances Not applicable

3.2 Mixtures

Hazardous

Chemical name	Weight-%	REACH Registration Number	EC No	Classification according to Regulation (EC) No. 1272/2008 [CLP]	Specific concentration limit (SCL)	M-Factor	M-Factor (long-term)
Linezolid 165800-03-3	0.2		Not Listed	STOT RE 2 (H373) Aquatic Acute 2 (H401) Aquatic Chronic 2 (H411)	Not Listed	No data available	No data available
Citric acid 77-92-9	*		201-069-1	Eye Irrit. 2A (H319)SE 3 (H335)	Not Listed	No data available	No data available
Sodium hydroxide 1310-73-2	**		215-185-5	Skin Corr.1A (H314)	Eye Irrit. 2 :: 0.5%<=C<2% Skin Corr. 1A :: C>=5% Skin Corr. 1B :: 2%<=C<5% Skin Irrit. 2 :: 0.5%<=C<2%	No data available	No data available
+ Hydrochloric Acid 7647-01-0	**		231-595-7	Acute Tox. 3 (H331) Skin Corr. 1A (H314) Press. Gas	Eye Irrit. 2 :: 10%<=C<25% Skin Corr. 1B :: C>=25% Skin Irrit. 2 :: 10%<=C<25% STOT SE 3 :: C>=10%	No data available	No data available

NonHazardous

Chemical name	Weight-%	REACH Registration Number	EC No	Classification according to Regulation (EC) No. 1272/2008 [CLP]	Specific concentration limit (SCL)	M-Factor	M-Factor (long-term)
Water 7732-18-5	*		231-791-2	No data available	Not Listed	No data available	No data available

SAFETY DATA SHEET

Product Name Linezolid Injection (Hospira, Inc.)
Revision date 18-Mar-2022

Page 3 / 14
Version 2

Dextrose 14431-43-7	*		Not Listed	No data available	Not Listed	No data available	No data available
SODIUM CHLORIDE 7647-14-5	*		231-598-3	No data available	Not Listed	No data available	No data available

Full text of H- and EUH-phrases: see section 16

Acute Toxicity Estimate

Chemical name	Oral LD50	Dermal LD50	Inhalation LC50 - 4 hour - dust/mist - mg/L	Inhalation LC50 - 4 hour - vapor - mg/L	Inhalation LC50 - 4 hour - gas - ppm
Water 7732-18-5	89838.9	No data available	No data available	No data available	No data available
Citric acid 77-92-9	5400	>2000	No data available	No data available	No data available
Sodium hydroxide 1310-73-2	325	1350	No data available	No data available	No data available
+ Hydrochloric Acid 7647-01-0	238	5010	No data available	No data available	563.3022
SODIUM CHLORIDE 7647-14-5	3000	10000	No data available	No data available	No data available

Additional information

+ Substance with a Union workplace exposure limit

* Proprietary

** to adjust pH

Non-hazardous ingredients provided for completeness. Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety. In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

Section 4: FIRST AID MEASURES

4.1. Description of first aid measures

Inhalation	Remove to fresh air. Seek immediate medical attention/advice.
Eye contact	Rinse thoroughly with plenty of water for at least 15 minutes, lifting lower and upper eyelids. Consult a physician.
Skin contact	Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.
Ingestion	Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

4.2. Most important symptoms and effects, both acute and delayed

Most important symptoms and effects For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

4.3. Indication of any immediate medical attention and special treatment needed

Note to physicians None.

SAFETY DATA SHEET

Product Name Linezolid Injection (Hospira, Inc.)
Revision date 18-Mar-2022

Page 4 / 14
Version 2

Section 5: FIRE-FIGHTING MEASURES

5.1. Extinguishing media

Suitable Extinguishing Media Dry chemical, CO₂, alcohol-resistant foam or water spray.

5.2. Special hazards arising from the substance or mixture

Specific hazards arising from the chemical Fine particles (such as dust and mists) may fuel fires/explosions.

Hazardous combustion products Formation of toxic gases is possible during heating or fire.

5.3. Advice for firefighters

Special protective equipment for fire-fighters Firefighters should wear self-contained breathing apparatus and full firefighting turnout gear. Use personal protection equipment.

Section 6: ACCIDENTAL RELEASE MEASURES

6.1. Personal precautions, protective equipment and emergency procedures

Personal precautions Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

For emergency responders Use personal protection recommended in Section 8.

6.2. Environmental precautions

Environmental precautions Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

6.3. Methods and material for containment and cleaning up

Methods for containment Prevent further leakage or spillage if safe to do so.

Methods for cleaning up Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean spill area thoroughly.

Prevention of secondary hazards Clean contaminated objects and areas thoroughly observing environmental regulations.

6.4. Reference to other sections

Reference to other sections See section 8 for more information. See section 13 for more information.

Section 7: HANDLING AND STORAGE

7.1. Precautions for safe handling

Advice on safe handling

Avoid breathing vapor or mist. Avoid contact with eyes, skin and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

General hygiene considerations Handle in accordance with good industrial hygiene and safety practice.

7.2. Conditions for safe storage, including any incompatibilities

Storage Conditions Store as directed by product packaging.

7.3. Specific end use(s)

SAFETY DATA SHEET

Product Name Linezolid Injection (Hospira, Inc.)
Revision date 18-Mar-2022

Page 5 / 14
Version 2

Specific use(s) Pharmaceutical drug product.

Section 8: EXPOSURE CONTROLS/PERSONAL PROTECTION

8.1. Control parameters

Exposure Limits

Refer to available public information for specific member state Occupational Exposure Limits.

Linezolid

Pfizer OEL TWA-8 Hr: 750 µg/m³

Citric acid

Czech Republic	4 mg/m ³
Germany	2 mg/m ³
	Ceiling / Peak: 4 mg/m ³
Germany	2 mg/m ³
Russia	MAC: 1 mg/m ³
Switzerland	2 mg/m ³
	STEL: 4 mg/m ³

Sodium hydroxide

ACGIH OEL (Ceiling)	2 mg/m ³
ACGIH TLV	Ceiling: 2 mg/m ³
Austria	2 mg/m ³
	STEL 4 mg/m ³
Bulgaria	2.0 mg/m ³
Czech Republic	1 mg/m ³
	Ceiling: 2 mg/m ³
Denmark	Ceiling: 2 mg/m ³
Estonia	1 mg/m ³
	STEL: 2 mg/m ³
Finland	Ceiling: 2 mg/m ³
France	2 mg/m ³
Hungary	1 mg/m ³
	STEL: 2 mg/m ³
Ireland	STEL: 2 mg/m ³
Ceiling Limit Value	2 mg/m ³
Latvia	0.5 mg/m ³
Poland	STEL: 1 mg/m ³
	0.5 mg/m ³
Romania	1 mg/m ³
	STEL: 3 mg/m ³
Slovakia	2 mg/m ³
Spain	STEL: 2 mg/m ³
Switzerland	2 mg/m ³
	STEL: 2 mg/m ³
OSHA PEL	2 mg/m ³
	(vacated) Ceiling: 2 mg/m ³
United Kingdom	STEL: 2 mg/m ³

+ Hydrochloric Acid

ACGIH OEL (Ceiling)	2 ppm
ACGIH TLV	Ceiling: 2 ppm
Austria	5 ppm
	8 mg/m ³
	STEL 10 ppm
	STEL 15 mg/m ³
Bulgaria	STEL: 10 ppm
	STEL: 15.0 mg/m ³
	5 ppm
	8.0 mg/m ³

SAFETY DATA SHEET

Product Name Linezolid Injection (Hospira, Inc.)
Revision date 18-Mar-2022

Page 6 / 14
Version 2

Czech Republic	8 mg/m ³ Ceiling: 15 mg/m ³
Denmark	Ceiling: 5 ppm Ceiling: 8 mg/m ³
Estonia	5 ppm 8 mg/m ³ STEL: 10 ppm STEL: 15 mg/m ³
European Union	TWA: 5 ppm TWA: 8 mg/m ³ STEL: 10 ppm STEL: 15 mg/m ³
Finland	STEL: 5 ppm STEL: 7.6 mg/m ³
Germany	2 ppm 3.0 mg/m ³ Ceiling / Peak: 4 ppm Ceiling / Peak: 6 mg/m ³
Germany	2 ppm 3 mg/m ³
Hungary	8 mg/m ³ STEL: 16 mg/m ³
Ireland	8 mg/m ³ 5 ppm STEL: 10 ppm STEL: 15 mg/m ³
Italy	5 ppm 8 mg/m ³ STEL: 10 ppm STEL: 15 mg/m ³
Ceiling Limit Value	2 ppm 3.0 mg/m ³
Latvia	5 ppm 8 mg/m ³ STEL: 10 ppm STEL: 15 mg/m ³
Netherlands	8 mg/m ³ STEL: 15 mg/m ³ STEL: 10 mg/m ³
Poland	5 mg/m ³ 5 ppm 8 mg/m ³ STEL: 10 ppm STEL: 15 mg/m ³
Romania	5 ppm 8 mg/m ³ STEL: 10 ppm STEL: 15 mg/m ³
Russia	MAC: 5 mg/m ³
Slovakia	5 ppm 8.0 mg/m ³
Spain	5 ppm 7.6 mg/m ³ STEL: 10 ppm STEL: 15 mg/m ³
Switzerland	2 ppm 3 mg/m ³ STEL: 4 ppm STEL: 6 mg/m ³
U.S. - OSHA - Final PELs - Ceiling Limits	5 ppm 7 mg/m ³
OSHA PEL	(vacated) Ceiling: 5 ppm (vacated) Ceiling: 7 mg/m ³ Ceiling: 5 ppm

SAFETY DATA SHEET

Product Name Linezolid Injection (Hospira, Inc.)
Revision date 18-Mar-2022

Page 7 / 14
Version 2

United Kingdom

Ceiling: 7 mg/m³
TWA: 1 ppm
TWA: 2 mg/m³
STEL: 5 ppm
STEL: 8 mg/m³

SODIUM CHLORIDE

Latvia
Russia

5 mg/m³
MAC: 5 mg/m³

SODIUM CHLORIDE

Pfizer Occupational Exposure
Band (OEB):

OEB 1 (control exposure to the range of 1000ug/m³ to 3000ug/m³)

8.2. Exposure controls

Engineering controls

Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

Environmental exposure controls

No information available.

Personal protective equipment

Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE). Contact your safety and health professional or safety equipment supplier for assistance in selecting the correct protective clothing/equipment based on an assessment of the workplace conditions, other chemicals used or present in the workplace and specific operational processes.

Eye/face protection

Wear safety glasses or goggles if eye contact is possible. (Eye protection must meet the standards in accordance with EN166, ANSI Z87.1 or international equivalent.).

Hand protection

Impervious gloves (e.g. Nitrile, etc.) are recommended if skin contact with drug product is possible and for bulk processing operations. (Protective gloves must meet the standards in accordance with EN374, ASTM F1001 or international equivalent.).

Skin and body protection

Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations. (Protective clothing must meet the standards in accordance with EN13982, ANSI 103 or international equivalent.).

Respiratory protection

Under normal conditions of use, if the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL (e.g. particulate respirator with a half mask, P3 filter). (Respirators must meet the standards in accordance with EN140, EN143, ASTM F2704-10 or international equivalent.).

General hygiene considerations

Handle in accordance with good industrial hygiene and safety practice.

Section 9: PHYSICAL AND CHEMICAL PROPERTIES

9.1. Information on basic physical and chemical properties

Physical state

Liquid

Color

Clear, colorless

Odor

No information available.

Odor threshold

No information available

Molecular formula

Mixture

Molecular weight

Mixture

Property

Values

pH

4.4-5.2

Melting point / freezing point

No data available

SAFETY DATA SHEET

Product Name Linezolid Injection (Hospira, Inc.)
Revision date 18-Mar-2022

Page 8 / 14
Version 2

Boiling point / boiling range	
Flash point	No information available
Evaporation rate	No data available
Flammability (solid, gas)	No data available
Flammability Limit in Air	
Upper flammability limit:	No data available
Lower flammability limit:	No data available
Vapor pressure	No data available
Vapor density	No data available
Relative density	No data available
Water solubility	No data available
Solubility(ies)	No data available
Partition coefficient	No data available
Autoignition temperature	No data available
Decomposition temperature	No data available
Kinematic viscosity	No data available
Dynamic viscosity	No data available
Particle characteristics	
Particle Size	No information available
Particle Size Distribution	No information available
Explosive properties	No information available

Partition Coefficient: (Method, pH, Endpoint, Value)

Linezolid
Measured 6-8 Log D 0.55

9.2. Other information

No information available

9.2.1. Information with regard to physical hazard classes

No information available

9.2.2. Other safety characteristics

No information available

Section 10: STABILITY AND REACTIVITY

10.1. Reactivity

Reactivity No data available.

10.2. Chemical stability

Stability Stable under normal conditions.

Explosion data

Sensitivity to Mechanical Impact No data available.

Sensitivity to Static Discharge No data available.

10.3. Possibility of hazardous reactions

Possibility of hazardous reactions No information available.

10.4. Conditions to avoid

Conditions to avoid Fine particles (such as dust and mists) may fuel fires/explosions.

10.5. Incompatible materials

Incompatible materials As a precautionary measure, keep away from strong oxidizers.

10.6. Hazardous decomposition products

Hazardous decomposition products No data available.

Section 11: TOXICOLOGICAL INFORMATION

SAFETY DATA SHEET

Product Name Linezolid Injection (Hospira, Inc.)
Revision date 18-Mar-2022

Page 9 / 14
Version 2

11.1. Information on hazard classes as defined in Regulation (EC) No 1272/2008

General Information: The information included in this section describes the potential hazards of the individual ingredients

Long Term: Repeat-dose studies in animals have shown a potential to cause adverse effects on reproductive system the developing fetus.

Known Clinical Effects: The most common adverse effects reported with clinical use were diarrhea, nausea, rash, and vomiting. Effects on blood and blood-forming organs have also occurred.

Acute Toxicity: (Species, Route, End Point, Dose)

Linezolid

Rat (F) Oral Minimum Lethal Dose 5000 mg/kg
Rat (M) Oral Minimum Lethal Dose > 5000 mg/kg
Dog Oral Minimum Lethal Dose > 2000 mg/kg

Citric acid

Mouse Oral LD50 5400 mg/kg

Sodium hydroxide

Mouse IP LD50 40 mg/kg

SODIUM CHLORIDE

Rat Sub-tenon injection (eye) LC50/1hr > 42 g/m³

Rat Oral LD 50 3 g/kg

Mouse Oral LD 50 4 g/kg

Rabbit Dermal LD 50 > 10 g/kg

Chemical name	Oral LD50	Dermal LD50	Inhalation LC50
Water	> 90 mL/kg (Rat)	-	-
Citric acid	= 3 g/kg (Rat)	> 2000 mg/kg (Rat)	-
Sodium hydroxide	= 325 mg/kg (Rat)	= 1350 mg/kg (Rabbit)	-
+ Hydrochloric Acid	238 - 277 mg/kg (Rat)	> 5010 mg/kg (Rabbit)	= 1.68 mg/L (Rat) 1 h
SODIUM CHLORIDE	= 3 g/kg (Rat)	> 10000 mg/kg (Rabbit)	> 42 mg/L (Rat) 1 h

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

Linezolid

Eye Irritation Rabbit Minimal

Skin Irritation Rabbit Minimal

Antigenicity- Passive cutaneous anaphylaxis Mouse Negative

Antigenicity- Active anaphylaxis Guinea Pig Negative

Citric acid

Eye Irritation Rabbit Severe

Skin Irritation Rabbit Mild

Sodium hydroxide

Eye Irritation Rabbit Severe

Skin Irritation Rabbit Severe

+ Hydrochloric Acid

Skin irritation Severe

Eye irritation Severe

SODIUM CHLORIDE

Skin irritation Rabbit Mild

Eye irritation Rabbit Mild

SAFETY DATA SHEET

Product Name Linezolid Injection (Hospira, Inc.)
Revision date 18-Mar-2022

Page 10 / 14
Version 2

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Linezolid

1 Month(s) Rat Oral 20 mg/kg/day NOAEL Blood forming organs, Blood
3 Month(s) Rat Oral 10 mg/kg/day NOAEL Blood forming organs, Blood
1 Month(s) Dog Oral 20 mg/kg/day NOAEL Blood forming organs, Blood, Gastrointestinal system
3 Month(s) Dog Oral 20 mg/kg/day NOAEL Blood forming organs, Blood, Gastrointestinal system

Reproduction & Development Toxicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Linezolid

Reproductive & Fertility Rat Oral 50 mg/kg/day NOAEL Fertility
Embryo / Fetal Development Rat Oral 2.5 mg/kg/day NOAEL Fetotoxicity, Not Teratogenic
Embryo / Fetal Development Rat Oral 15 mg/kg/day NOAEL Maternal Toxicity
Embryo / Fetal Development Mouse Oral 150 mg/kg/day NOAEL Fetotoxicity, Maternal Toxicity, Not Teratogenic

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Linezolid

In Vitro Unscheduled DNA Synthesis Negative
Bacterial Mutagenicity (Ames) *Salmonella* Negative
In Vitro Chromosome Aberration Human Lymphocytes Negative
In Vivo Micronucleus Mouse Negative

+ Hydrochloric Acid

Bacterial Mutagenicity (Ames) *Salmonella* Negative
In Vivo Micronucleus Rat Negative

Carcinogenicity

None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

+ Hydrochloric Acid

IARC

Group 3 (Not Classifiable)

11.2. Information on other hazards

11.2.1. Endocrine disrupting properties

Endocrine disrupting properties No information available.

11.2.2. Other information

Other adverse effects

No information available.

Section 12: ECOLOGICAL INFORMATION

Environmental Overview:

Environmental properties have not been investigated. Releases to the environment should be avoided.

12.1. Toxicity

Aquatic Toxicity: (Species, Method, End Point, Duration, Result)

Linezolid

Daphnia magna (Water Flea) OECD EC50 48 hours > 100 mg/L
Oncorhynchus mykiss (Rainbow Trout) OECD LC50 96 hours > 1.4 mg/L
Anabaena flos-aquae (Cyanobacteria) Algae OECD ErC50 96 hours 2.0 mg/L
Anabaena flos-aquae (Cyanobacteria) OECD NOEC 96 hours 1.0 mg/L

Bacterial Inhibition: (Inoculum, Method, End Point, Result)

Linezolid

Activated sludge OECD EC50 / EC15 > 1000 mg/L
Aspergillus niger (Fungus) OECD MIC 600 mg/L
Trichoderma viride (Fungus) OECD MIC > 1000 mg/L
Clostridium perfringens (Bacterium) OECD MIC 2 mg/L
Bacillus subtilis (Bacterium) OECD MIC 0.4 mg/L

Chronic Aquatic Toxicity: (Species, Method, Duration, Endpoint, Result, Adverse Endpoint)

SAFETY DATA SHEET

Product Name Linezolid Injection (Hospira, Inc.)
Revision date 18-Mar-2022

Page 11 / 14
Version 2

Linezolid

Pimephales promelas (Fathead Minnow) OECD 32 Day(s) NOEC 9.9 mg/L Sublethal effects
Daphnia magna (Water Flea) OECD 21 Day(s) NOEC 24 mg/L Reproduction
Ceriodaphnia dubia (Daphnids) OECD 7 Day(s) NOEC 31 mg/L Reproduction, Survival

12.2. Persistence and degradability

Persistence and degradability

Biodegradation: (Method, Inoculum, Biodeg Study, Result, Endpoint, Duration, Classification)

Linezolid

OECD Activated sludge Die-away, Mineralization (CO2 Evolution) 84 % in 28 Day(s)
OECD Activated sludge Mineralization (CO2 Evolution) -3.4% Not readily biodegradable
OECD Water - Sediment (various) Mineralization (CO2 Evolution) 44 - 52.7 % in 102 Day(s)
OECD Water - Sediment (various) Total System DT50 23 - 24.7 Day(s)

12.3. Bioaccumulative potential

Bioaccumulation

Partition Coefficient: (Method, pH, Endpoint, Value)

Linezolid

Measured 6-8 Log D 0.55

12.4. Mobility in soil

Mobility in soil

Sorption:

Linezolid (165800-03-3)

<u>Method</u>	<u>Inoculum</u>	<u>End Point</u>	<u>Result</u>
OECD	Activated sludge	Kd	3.0
OECD	Activated sludge	Koc	8.6
OECD	Soil (various)	Kd (Geometric mean)	18.8
OECD	Soil (various)	Koc (Geometric mean)	922

12.5. Results of PBT and vPvB assessment

PBT and vPvB assessment

Chemical name	PBT and vPvB assessment
Citric acid	The substance is not PBT / vPvB
Sodium hydroxide	The substance is not PBT / vPvB PBT assessment does not apply
+ Hydrochloric Acid	The substance is not PBT / vPvB PBT assessment does not apply
SODIUM CHLORIDE	The substance is not PBT / vPvB PBT assessment does not apply

12.6. Endocrine disrupting properties

Endocrine disrupting properties No information available.

12.7. Other adverse effects

No information available.

Section 13: DISPOSAL CONSIDERATIONS

SAFETY DATA SHEET

Product Name Linezolid Injection (Hospira, Inc.)
Revision date 18-Mar-2022

Page 12 / 14
Version 2

13.1. Waste treatment methods

Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural wastewater and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

Section 14: TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

Section 15: REGULATORY INFORMATION

15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

Water

CERCLA/SARA Section 313 de minimus %	Not Listed
California Proposition 65	Not Listed
TSCA	Present
EINECS	231-791-2
AICS	Present

Dextrose

CERCLA/SARA Section 313 de minimus %	Not Listed
California Proposition 65	Not Listed
EINECS	Not Listed
AICS	Present

Linezolid

CERCLA/SARA Section 313 de minimus %	Not Listed
California Proposition 65	Not Listed
EINECS	Not Listed
Standard for Uniform Scheduling of Medicines and Poisons (SUSMP)	Schedule 4

Citric acid

CERCLA/SARA Section 313 de minimus %	Not Listed
California Proposition 65	Not Listed
TSCA	Present
EINECS	201-069-1
AICS	Present

Sodium hydroxide

CERCLA/SARA Section 313 de minimus %	Not Listed
Hazardous Substances RQs	1000 lb
California Proposition 65	Not Listed
TSCA	Present
EINECS	215-185-5
AICS	Present
Standard for Uniform Scheduling of Medicines and Poisons (SUSMP)	Schedule 5 Schedule 6

+ Hydrochloric Acid

SAFETY DATA SHEET

Product Name Linezolid Injection (Hospira, Inc.)
Revision date 18-Mar-2022

Page 13 / 14
Version 2

CERCLA/SARA Section 313 de minimus %	1.0 %
Hazardous Substances RQs	5000 lb
California Proposition 65	Not Listed
TSCA	Present
EINECS	231-595-7
AICS	Present
Standard for Uniform Scheduling of Medicines and Poisons (SUSMP)	Schedule 5 Schedule 6
SODIUM CHLORIDE	
CERCLA/SARA Section 313 de minimus %	Not Listed
California Proposition 65	Not Listed
TSCA	Present
EINECS	231-598-3
AICS	Present

France

Occupational Illnesses (R-463-3, France)

Chemical name	French RG number	Title
SODIUM CHLORIDE 7647-14-5	RG 78	-

European Union

Take note of Directive 98/24/EC on the protection of the health and safety of workers from the risks related to chemical agents at work

Authorizations and/or restrictions on use:

This product contains one or more substance(s) subject to restriction (Regulation (EC) No. 1907/2006 (REACH), Annex XVII)

Chemical name	Restricted substance per REACH Annex XVII	Substance subject to authorization per REACH Annex XIV
Sodium hydroxide - 1310-73-2	Use restricted. See item 75.	
+ Hydrochloric Acid - 7647-01-0	Use restricted. See item 75.	

Persistent Organic Pollutants

Not applicable

Ozone-depleting substances (ODS) regulation (EC) 1005/2009

Not applicable

Named dangerous substances per Seveso Directive (2012/18/EU)

Chemical name	Lower-tier requirements (tons)	Upper-tier requirements (tons)
+ Hydrochloric Acid - 7647-01-0	25	250

Plant protection products directive (91/414/EEC)

Chemical name	Plant protection products directive (91/414/EEC)
SODIUM CHLORIDE - 7647-14-5	Plant protection agent

EU - Biocides

Chemical name	EU - Biocides
Citric acid - 77-92-9	Product-type 1: Human hygiene
+ Hydrochloric Acid - 7647-01-0	Product-type 2: Disinfectants and algaecides not intended for direct application to humans or animals

Legend:

TSCA - United States Toxic Substances Control Act Section 8(b) Inventory

EINECS/ELINCS - European Inventory of Existing Chemical Substances/European List of Notified Chemical Substances

AICS - Australian Inventory of Chemical Substances

SAFETY DATA SHEET

Product Name Linezolid Injection (Hospira, Inc.)
Revision date 18-Mar-2022

Page 14 / 14
Version 2

15.2. Chemical safety assessment

Chemical Safety Report No information available

Section 16: OTHER INFORMATION

Key or legend to abbreviations and acronyms used in the safety data sheet

Full text of H-Statements referred to under section 3

Specific target organ toxicity, repeated exposure-Cat.2; H373 - May cause damage to organs through prolonged or repeated exposure. Specific target organ toxicity, single exposure; Respiratory tract irritation-Cat.3; H335 - May cause respiratory irritation. Skin corrosion/irritation-Cat.1A; Skin corrosion/irritation-Cat.1B; H314 - Causes severe skin burns and eye damage. Hazardous to the aquatic environment, acute toxicity-Cat.2; H401 - Toxic to aquatic life. Hazardous to the aquatic environment, chronic toxicity-Cat.2; H411 - Toxic to aquatic life with long lasting effects.

Data Sources: Pfizer proprietary drug development information. Safety data sheets for individual ingredients.

Reason for revision Updated Section 1 - Identification of the Substance/Preparation and the Company/Undertaking. Updated Section 3 - Composition / Information on Ingredients. Updated Section 11 - Toxicology Information. Updated Section 12 - Ecological Information. Updated Section 15 - Regulatory Information. Updated Section 16 - Other Information.

Revision date 18-Mar-2022

Prepared By Pfizer Global Environment, Health, and Safety

Pfizer Inc believes that the information contained in this Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.